From TXT to XML: New Sequence Listing Standard Takes Effect on July 1, 2022

June 27, 2022

On July 1, 2022, a new sequence listing format, World Intellectual Property Organization (WIPO) Standard ST.26, will replace the current ST.25 standard in the WIPO and in the national patent offices of all WIPO member states.[1],[2] There is no transition period between the standards, and thus, all applications with a filing date of July 1,… Read more »

PCT and USPTO Fee Increase – October 1 and 2, 2020

September 28, 2020

PCT and USPTO fees are scheduled to increase on October 1 and October 2, 2020, respectively. In view of the fee increases, applicants may wish to file new applications, file post-grant requests, and/or submit documents in existing applications that require any fee payment, prior to October 1, 2020 (for new PCT applications) or October 2,… Read more »

Notices of Allowance With Incorrect Issue Fee

September 22, 2020

On September 15, 2020, the United States Patent and Trademark Office (USPTO) issued an Advisory 1 that Notices of Allowance mailed during the period of September 9-15, 2020, may specify an incorrect Issue Fee amount. Due to a technical problem at the USPTO, most Notices of Allowance mailed between September 9, 2020, and September 15, 2020, specify… Read more »

Patents 4 Partnership – USPTO’s COVID-19 Marketplace Forum

May 18, 2020

On May 4, 2020, the United States Patent and Trademark Office (USPTO) unveiled a web-based Intellectual Property (IP) marketplace platform “Patents 4 Partnerships,” (, a searchable database of patents and published patent applications relating to the coronavirus (COVID-19) pandemic that are available for licensing. The Patents 4 Partnership database is searchable by keyword, patent number,… Read more »

Objective Indicia of Non-Obviousness – Finding a Nexus Between Evidence and a Claimed Combination

May 18, 2020

Objective indicia (OI) of non-obviousness, sometimes called secondary considerations, can be powerful tools for addressing obviousness rejections during prosecution. The Federal Circuit frequently reminds us that “evidence of secondary considerations may often be the most probative and cogent evidence in the record.”1 But, for this evidence to be probative, there must be a nexus between the… Read more »

Update: Orange Book Listing of Drug Delivery Device Patents After In re Lantus, February 2020

April 21, 2020

Update: Orange Book Listing of Drug Delivery Device Patents After In re Lantus, February 20201 Introduction The U.S. Court of Appeals for the First Circuit recently ruled that Sanofi could potentially be held liable for an antitrust violation for improperly listing an insulin delivery device-related patent in the U.S. Food and Drug Administration’s (“FDA”) Orange… Read more »

Subject Matter Eligibility Retrospective: Informative PTAB Decisions Applying the 2019 Revised Guidance

March 30, 2020

It has long been recognized that, at a certain level, almost all patent claims include some abstract concepts. One of the hurdles facing practitioners and Examiners alike in determining subject matter eligibility under Section 101 has been drawing the line between claims that are “directed to” an abstract idea under the first step of the… Read more »

Author: Richard Hanna

Let's Get Started

Tel: (703) 712-8531

Medler Ferro Woodhouse & Mills PLLC
8201 Greensboro Drive, Suite 1060
McLean, VA 22102

Phone and Fax
tel: (703) 712-8531
fax: (703) 712-8525